The P-III (TACKLE) trial evaluates Evusheld (600mg, IM) vs PBO in a ratio (1:1) in 903 outpatients aged ≥18yrs. who were non-hospitalized with COVID-19 & symptomatic for ≤7 days at 95 sites in the US, Latin America, EU & Japan
The 1EPs of the study showed a 50% reduction in relative risk of progressing to sev. COVID-19 or death from any cause @29 days. In 2EPs, 72% reduction in risk of respiratory failure with 3 patients (0.7% vs 3%) requiring measures i.e., mechanical ventilation or ECMO & the results were published in The Lancet Respiratory Medicine
In prespecified analysis, 88% & 67% reduction in risk of developing sev. COVID-19 or death from any cause within 3 & 5 days of symptom onset & was well-tolerated
Ref: AstraZeneca | Image: AstraZeneca
